Filtered By:
Source: Heart Rhythm
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 356 results found since Jan 2013.

New-onset atrial fibrillation and thromboembolic risk: Cardiovascular syzygy?
Atrial fibrillation (AF) is a condition that confers increased thromboembolic risk. Oral anticoagulant (OAC) therapy can attenuate this risk. However, use of OAC therapy is determined largely by the presence of additional clinical factors (encapsulated by the CHA2DS2VASc score) that incrementally elevate stroke risk. Currently, there is no specific recommendation regarding urgency of initiation of OAC therapy in the presence of new-onset AF, except where cardioversion is being considered. Recently, it has become increasingly apparent that there is a period immediately following the onset of AF of particularly accentuated t...
Source: Heart Rhythm - December 9, 2015 Category: Cardiology Authors: Nathan E.K. Procter, Simon Stewart, John D. Horowitz Tags: Contemporary Review Source Type: research

Left Atrial Appendage Morphology Assessment for Risk Stratification of Embolic Stroke in Patients with Atrial Fibrillation. A Meta-Analysis
Thromboembolic Event (TE) risk stratification is performed by using CHA2DS2Vasc Score. It has been suggested that left atrial appendage (LAA) morphology independently influences TE risk in patients with non-valvular atrial fibrillation (AF). The LAA morphology has been classified into four different types: Chicken Wing, Cauliflower, Windsock and Cactus.
Source: Heart Rhythm - March 21, 2016 Category: Cardiology Authors: Florentino Lupercio, Juan Carlos Ruiz, David F. Briceno, Jorge Romero, Pedro A. Villablanca, Cecilia Berardi, Robert Faillace, Andrew Krumerman, John D. Fisher, Kevin Ferrick, Mario Garcia, Andrea Natale, Luigi Di Biase Source Type: research

Association between Atrial Fibrillation and Volumetric MRI Brain Measures: Framingham Offspring Study
The increased risk of stroke and cognitive impairment associated with atrial fibrillation (AF) is well documented. However, there is a paucity of research investigating the relations between AF and brain morphology.
Source: Heart Rhythm - July 10, 2016 Category: Cardiology Authors: Ryan J. Piers, Arvind Nishtala, Sarah R. Preis, Charles DeCarli, Philip A. Wolf, Emelia J. Benjamin, Rhoda Au Source Type: research

Association between atrial fibrillation and volumetric magnetic resonance imaging brain measures: Framingham Offspring Study
The increased risk of stroke and cognitive impairment associated with atrial fibrillation (AF) is well documented. However, there is a paucity of research investigating the relations between AF and brain morphology.
Source: Heart Rhythm - July 10, 2016 Category: Cardiology Authors: Ryan J. Piers, Arvind Nishtala, Sarah R. Preis, Charles DeCarli, Philip A. Wolf, Emelia J. Benjamin, Rhoda Au Source Type: research

Extracranial arterial and venous thromboembolism in patients with atrial fibrillation: A meta-analysis of randomized controlled trials
Thromboembolism prevention is central to atrial fibrillation (AF) management. Randomized controlled trials (RCTs) have primarily focused on stroke prevention. Detailed analyses of extracranial thromboembolic events, particularly in patients with low dose non-vitamin K antagonist oral anticoagulants (NOACs), are scarce.
Source: Heart Rhythm - January 2, 2017 Category: Cardiology Authors: Kang-Ling Wang, Harry R. B üller, Shinya Goto, Chun-Yi Lin, En-Yu Lai, Chun-Chih Chiu, Chern-En Chiang, Robert P. Giugliano Source Type: research

Benefits of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation go beyond stroke prevention
Source: Heart Rhythm - January 15, 2017 Category: Cardiology Authors: Jay A. Montgomery, Gregory F. Michaud Source Type: research

Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: A propensity-matched analysis
Catheter ablation reduces recurrence of atrial fibrillation and improves quality of life. Only few studies have assessed the effect of catheter ablation on long-term outcomes.
Source: Heart Rhythm - February 7, 2017 Category: Cardiology Authors: Walid Saliba, Jorge E. Schliamser, Idit Lavi, Ofra Barnett-Griness, Naomi Gronich, Gad Rennert Source Type: research

Percutaneous left atrial appendage closure improves left atrial mechanical function through Frank –Starling mechanism
Modifications in left atrial (LA) flow velocities after left atrial appendage (LAA) exclusion have been shown in animal and ex  vivo models. In a substudy of PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation), an objective improvement in quality of life was observed after LAA closure.
Source: Heart Rhythm - February 6, 2017 Category: Cardiology Authors: Augustin Coisne, Rosario Pilato, Fran çois Brigadeau, Didier Klug, Christelle Marquie, Zouheir Souissi, Marjorie Richardson, Stéphanie Mouton, Anne-Sophie Polge, Patrizio Lancellotti, Dominique Lacroix, David Montaigne Source Type: research

EWOLUTION – The Next Evolution in Appendage Closure?
Oral anticoagulation (OAC) is a class I indication for patients with non-valvular atrial fibrillation (AF) and 2 or more risk factors for stroke.1 However, many patients with AF are ineligible for OAC due to prohibitive bleeding. Subsequently, as a result of the pivotal role of the left atrial appendage (LAA) in the formation of thrombi, an alternative strategy to OAC is occlusion of the LAA.2 The WATCHMAN device (Boston Scientific Corporation, Marlborough, Massachusetts) is the only FDA approved LAA occlusion product studied in the randomized control trials (RCT) (Table 1).
Source: Heart Rhythm - June 22, 2017 Category: Cardiology Authors: Muhammad R. Afzal, Emile G. Daoud Source Type: research

EWOLUTION —The next evolution in appendage closure?
Oral anticoagulation (OAC) is a class I indication for patients with nonvalvular atrial fibrillation (AF) and ≥2 risk factors for stroke.1 However, many patients with AF are ineligible for OAC because of prohibitive bleeding. Subsequently, as a result of the pivotal role of the left atrial appendage (LAA) in the formation of thrombi, an alternative strategy to OAC is occlusion of the LAA.2 The WATCHMAN de vice (Boston Scientific Corporation, Marlborough, MA) is the only US Food and Drug Administration (FDA)–approved LAA occlusion product that has been studied in randomized control trials (RCTs) (Table).
Source: Heart Rhythm - June 22, 2017 Category: Cardiology Authors: Muhammad R. Afzal, Emile G. Daoud Tags: Editorial Commentary Source Type: research

EP News: Basic and Translational
Atrial fibrillation affects more than 33 million people worldwide and increases the risk of stroke, heart failure, and death. Fourteen genetic loci have been associated with atrial fibrillation in European and Asian ancestry groups. To further define the genetic basis of atrial fibrillation, Christophersen et  al (Nat Genet 2017;49:946, PMID 28416818) performed large-scale, transancestry meta-analyses of common and rare variant association studies. The genome-wide association studies included 17,931 individuals with atrial fibrillation and 115,142 referents; the exome-wide association studies and rare v ariant association...
Source: Heart Rhythm - August 23, 2017 Category: Cardiology Authors: Penelope A. Boyden Tags: EP News: Basic and Translational Source Type: research

Utility and Limitations of Long-Term Monitoring of Atrial Fibrillation Using an Implantable Loop Recorder
Atrial fibrillation (AF) is the most common cardiac arrhythmia diagnosed and treated in the world. The treatment of patients ’ symptoms as well as the prevention of stroke and heart failure is dependent on accurate detection and characterization of AF. A variety of electrocardiographic (ECG) monitoring techniques are being used for these purposes. However, these intermittent ECG monitoring techniques have been shown to under diagnose AF events, while having limited ability to characterize AF burden and density.
Source: Heart Rhythm - September 13, 2017 Category: Cardiology Authors: Randall Lee, Suneet Mittal Source Type: research

Atrial Fibrillation and Cognitive Decline —Another Piece for a Big Puzzle
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is increasing over time.1, 2 AF is associated with an increased risk of stroke,3 heart failure,4 and death.5-7 In recent years, evidence has emerged to indicate that AF is associated with another growing public health problem: cognitive impairment and dementia.8 Although the evidence is compelling, existing studies suffer from several limitations such as reliance on the Mini-Mental State Examination, cross-sectional design, and lack of attention to domain-specific changes.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: Lin Y. Chen, Win-Kuang Shen Source Type: research

Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: comparison between uninterrupted direct oral anticoagulants and warfarin administration
The effect of uninterrupted oral anticoagulant use in patients with chronic kidney disease (CKD) during catheter ablation for atrial fibrillation (AF) is not fully understood.
Source: Heart Rhythm - October 26, 2017 Category: Cardiology Authors: Satoshi Yanagisawa, Yasuya Inden, Aya Fujii, Monami Ando, Junya Funabiki, Yosuke Murase, Masaki Takenaka, Noriaki Otake, Yoshihiro Ikai, Yusuke Sakamoto, Rei Shibata, Toyoaki Murohara Source Type: research